Lakewood-Amedex Pursues 8x Authorized Share Expansion and Blank-Check Reverse Split Authority

summarizeSummary

Lakewood-Amedex's preliminary proxy seeks shareholder approval for an 8x authorized share increase to 100 million shares and board authority to execute reverse splits up to 1:20, setting the stage for massive potential dilution amid a going-concern warning.

check_boxKey Events · Corporate Governance and Compliance · LABT

• 8x Authorized Share Increase Proposed

  Proposal 2 seeks to increase authorized common shares from 12.5 million to 100 million, creating 97.4 million unissued shares — an 8x expansion that would give the board broad dilution capacity without further shareholder approval.

• Blank-Check Reverse Split Authority

  Proposal 3 asks shareholders to authorize the board to execute one or more reverse stock splits at a cumulative ratio up to 1:20 through September 2027, primarily to maintain Nasdaq's $1 minimum bid price. The board would have sole discretion on timing and ratio.

• Equity Plan Expansion Adds Dilution

  Proposal 4 would increase the 2020 Equity Incentive Plan by 216,495 shares to 400,000 total, further diluting existing holders. Only 56,508 shares remain available under the current plan.

• Going Concern Backdrop Raises Stakes

  The company's last 10-Q (May 2026) disclosed a persistent going-concern warning and low cash, making these capital-raising tools critical for survival but highly dilutive for current shareholders.

auto_awesomeAnalysis · LABT · Life Sciences

Shareholders are being asked to approve an 8x increase in authorized common shares — from 12.5 million to 100 million — along with a blank-check authorization that would let the board execute reverse stock splits up to 1:20 through September 2027. With only 2.37 million shares outstanding and a going-concern warning already in place, the 97.4 million new shares would hand management enormous dilution capacity without further shareholder votes. The reverse split authority is explicitly tied to maintaining Nasdaq's $1 minimum bid price, but the combination of these proposals signals a company preparing for aggressive capital raising that could massively dilute existing holders. Adding another layer of potential dilution, the proxy also seeks to increase the equity plan by 216,495 shares. Against the backdrop of a recent 1-for-10 reverse split in June 2026 and a persistent going-concern warning, these proposals represent a critical governance moment for shareholders.